New Long-Term Data Shows Lebrikizumab Sustains Atopic Dermatitis Clearance With Less Frequent Dosing and Advances Findings from Dr. Philip Werschler of Spokane Dermatology Clinic

Long-term data from the ADjoin trial demonstrates that lebrikizumab (Ebglyss), an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance for up to 2 years with less frequent monthly dosing instead of biweekly administration. Nearly 80% of patients on monthly dosing maintained clear or almost clear skin, with 76% achieving IGA scores of 0 or 1, while maintaining a consistent safety profile.

06/22/2026, 2:55 PM • GlobeNewswire

Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis

Sitryx Therapeutics announced completion of enrollment in its Phase 1b clinical trial of SYX-5219, a first-in-class oral PKM2 modulator for moderate to severe atopic dermatitis, ahead of schedule. The trial enrolled 50 patients across US and European sites and is expected to readout in Q4 2026. The milestone follows positive Phase 1a data showing safety and immunomodulation of type 2 inflammation.

06/22/2026, 7:00 AM • GlobeNewswire

TheDoseReport Announces Which GLP-1 is Best? Semaglutide and Tirzepatide

TheDoseReport.com published a comprehensive comparison of GLP-1 medications, analyzing semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) for weight management. The analysis highlights that tirzepatide demonstrates greater average weight loss (20.2%) compared to semaglutide (13.7%), though both are effective. The article emphasizes the importance of consulting healthcare professionals and considering individual factors including medical history, cost, side effects, and lifestyle support when choosing between these medications.

06/21/2026, 7:33 AM • GlobeNewswire

Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?

Eli Lilly is thriving in the GLP-1 weight-loss drug market with strong sales growth, but offers minimal dividend yield of 0.6%. Pfizer, struggling with patent expirations and GLP-1 setbacks, offers a much higher 6.6% dividend yield. While Pfizer faces near-term headwinds, income-focused investors willing to accept risk may find value in its substantial dividend, though the payout ratio exceeding 100% raises concerns.

06/20/2026, 5:15 PM • The Motley Fool

The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own

The next wave of AI adoption is shifting from tool-builders to companies applying AI in real-world drug development. Eli Lilly leverages AI partnerships with OpenAI and Nvidia for drug discovery while expanding its weight-loss portfolio, showing strong financial growth. Twist Bioscience supplies synthetic DNA for drug testing and benefits from Amazon's new Bio Discovery platform, offering higher-risk growth potential.

06/19/2026, 4:30 AM • The Motley Fool

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.

06/18/2026, 1:00 PM • GlobeNewswire

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

The healthcare sector is rebounding after a lackluster start to 2026, driven by rotation from tech and stabilizing costs. Three stocks are leading the rally: Eli Lilly (up 11% in a month) on strong GLP-1 drug sales and new oral pill approval; Humana (up 18% in a month) as medical utilization moderates and margins widen; and DexCom (up 15% in a month) expanding into non-insulin Type 2 diabetes markets with landmark trial data.

06/18/2026, 11:41 AM • Investing

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

3 Under-the-Radar Stocks to Buy and Hold for a Decade

The article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.

06/16/2026, 3:30 AM • The Motley Fool

Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026

Confo Therapeutics presented preclinical data for CFTX-2034, an SSTR5 agonistic antibody candidate for post-bariatric hypoglycemia (PBH), at ENDO 2026. The data demonstrate dose-dependent suppression of insulin and GLP-1 secretion, selective pharmacology, and a long half-life supporting once-monthly dosing. The company plans to advance CFTX-2034 through IND-enabling studies toward Phase 1 clinical development.

06/15/2026, 3:00 PM • GlobeNewswire

Novo Nordisk’s Wegovy Pill Turns Pricing Pain Into a Volume Bet

Novo Nordisk's stock has collapsed 67% from its June 2024 peak to the mid-$40s due to U.S. pricing pressures, competition, and its own decision to price the Wegovy pill at just $149/month as a volume-over-price strategy. While Q1 results showed 22% obesity-care growth and the company raised guidance, the market remains skeptical about whether the pricing power will recover. The stock trades near multi-year lows with scattered analyst targets ranging from $40 to $175, reflecting fundamental disagreement on the turnaround thesis. Management's DKK 15 billion buyback signals conviction, but Eli Lilly's competitive advantage and policy headwinds continue to weigh on sentiment.

06/15/2026, 2:07 PM • Investing

Eli Lilly Eyes Label Expansion For Leukemia Drug

Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial met its primary endpoint, showing that adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia. The combination reduced disease progression or death risk by 45% compared to the two-drug regimen alone, with benefits observed across high-risk patient groups. Lilly plans to submit results to regulatory authorities for label expansion.

06/15/2026, 1:43 PM • Benzinga

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lilly stock has surged over 400% in five years and reached a $1 trillion market cap, driven by its GLP-1 weight loss drugs Mounjaro and Zepbound. While the stock trades at a premium valuation of 40x trailing earnings, the company's strong earnings growth, strategic acquisitions in RNA therapies and infectious diseases, and long-term growth prospects make it a compelling buy for long-term investors willing to hold for 5+ years, despite potential short-term volatility.

06/15/2026, 12:30 PM • The Motley Fool

3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow

Eli Lilly is a leader in the GLP-1 weight-loss drug market with exceptional sales growth for Mounjaro and Zepbound. Despite a high P/E ratio of 40x, the company is growing into its valuation. Eli Lilly continues to innovate with GLP-1 pill versions and is strategically acquiring companies in infectious disease to build a diversified portfolio beyond GLP-1 drugs as patent protection eventually expires.

06/14/2026, 8:15 AM • The Motley Fool

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About

Pfizer's berobenatide, a GLP-1 receptor agonist anti-obesity drug, demonstrated comparable weight-loss results (15.9% at 32 weeks) to competitors but with a key advantage: monthly injections instead of weekly ones. With 10 trials in or entering phase 3 and 20+ anti-obesity treatments in development, Pfizer is positioning itself as a serious competitor to market leaders Eli Lilly and Novo Nordisk. However, significant revenue contributions won't materialize until 2029, and increased competition will likely erode pricing power for existing weight-loss drugs.

06/12/2026, 12:32 PM • The Motley Fool